TY  - JOUR
AU  - Vukadinović, Aleksandar
AU  - Milanović, Zorana
AU  - Ognjanović, Miloš
AU  - Janković, Drina
AU  - Radović, Magdalena
AU  - Mirković, Marija D.
AU  - Karageorgou, Maria-Argyro
AU  - Bouziotis, Penelope
AU  - Erić, Slavica
AU  - Vranješ-Đurić, Sanja
AU  - Antić, Bratislav
AU  - Prijović, Željko
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10368
AB  - Radiolabelled superparamagnetic iron oxide nanoparticles (SPIONs) are a promising nanomaterial for the development of dual radiation/hyperthermia cancer therapy. To that purpose, flower-shaped SPIONs with an exceptional heating capability were synthesised and coated with citrate, dextran or (3-aminopropyl)triethoxysilane. Both non-coated and coated SPIONs were nontoxic to CT-26 mouse colon cancer cells up to 1.0 mg ml−1 in vitro. In an oscillating magnetic field, citrate-coated SPIONs (CA/SPIONs) displayed the highest heating rate (SAR ∼ 253 W g−1) and the strongest hyperthermia effects against CT-26 cells. Labelling of the CA/SPIONs by the 90Y radionuclide, emitting β− radiation with an average/maximum energy of 0.94/2.23 MeV, and deep tissue penetration generated 90Y-CA/SPIONs intended for the therapy of solid tumours. However, intravenous injection of 90Y-CA/SPIONs in CT-26 xenograft-bearing mice resulted in low tumour accumulation. On the contrary, intratumoural injection resulted in long-term retention at the injection site. A single intratumoural injection of 0.25 mg CA/SPIONs followed by 30-min courses of magnetic hyperthermia for four consecutive days caused a moderate antitumour effect against CT-26 and 4T1 mouse tumour xenografts. Intratumoural application of 1.85 MBq/0.25 mg 90Y-CA/SPIONs, alone or combined with hyperthermia, caused a significant (P ≤ 0.01) antitumour effect without signs of systemic toxicity. The results confirm the suitability of 90Y-CA/SPIONs for monotherapy or dual magnetic hyperthermia-radionuclide nanobrachytherapy (NBT) of solid tumours.
T2  - Nanotechnology
T1  - 90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours
VL  - 33
IS  - 40
SP  - 405102
DO  - 10.1088/1361-6528/ac7ac0
ER  - 

@article{
author = "Vukadinović, Aleksandar and Milanović, Zorana and Ognjanović, Miloš and Janković, Drina and Radović, Magdalena and Mirković, Marija D. and Karageorgou, Maria-Argyro and Bouziotis, Penelope and Erić, Slavica and Vranješ-Đurić, Sanja and Antić, Bratislav and Prijović, Željko",
year = "2022",
abstract = "Radiolabelled superparamagnetic iron oxide nanoparticles (SPIONs) are a promising nanomaterial for the development of dual radiation/hyperthermia cancer therapy. To that purpose, flower-shaped SPIONs with an exceptional heating capability were synthesised and coated with citrate, dextran or (3-aminopropyl)triethoxysilane. Both non-coated and coated SPIONs were nontoxic to CT-26 mouse colon cancer cells up to 1.0 mg ml−1 in vitro. In an oscillating magnetic field, citrate-coated SPIONs (CA/SPIONs) displayed the highest heating rate (SAR ∼ 253 W g−1) and the strongest hyperthermia effects against CT-26 cells. Labelling of the CA/SPIONs by the 90Y radionuclide, emitting β− radiation with an average/maximum energy of 0.94/2.23 MeV, and deep tissue penetration generated 90Y-CA/SPIONs intended for the therapy of solid tumours. However, intravenous injection of 90Y-CA/SPIONs in CT-26 xenograft-bearing mice resulted in low tumour accumulation. On the contrary, intratumoural injection resulted in long-term retention at the injection site. A single intratumoural injection of 0.25 mg CA/SPIONs followed by 30-min courses of magnetic hyperthermia for four consecutive days caused a moderate antitumour effect against CT-26 and 4T1 mouse tumour xenografts. Intratumoural application of 1.85 MBq/0.25 mg 90Y-CA/SPIONs, alone or combined with hyperthermia, caused a significant (P ≤ 0.01) antitumour effect without signs of systemic toxicity. The results confirm the suitability of 90Y-CA/SPIONs for monotherapy or dual magnetic hyperthermia-radionuclide nanobrachytherapy (NBT) of solid tumours.",
journal = "Nanotechnology",
title = "90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours",
volume = "33",
number = "40",
pages = "405102",
doi = "10.1088/1361-6528/ac7ac0"
}

Vukadinović, A., Milanović, Z., Ognjanović, M., Janković, D., Radović, M., Mirković, M. D., Karageorgou, M., Bouziotis, P., Erić, S., Vranješ-Đurić, S., Antić, B.,& Prijović, Ž.. (2022). 90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours. in Nanotechnology, 33(40), 405102.
https://doi.org/10.1088/1361-6528/ac7ac0

Vukadinović A, Milanović Z, Ognjanović M, Janković D, Radović M, Mirković MD, Karageorgou M, Bouziotis P, Erić S, Vranješ-Đurić S, Antić B, Prijović Ž. 90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours. in Nanotechnology. 2022;33(40):405102.
doi:10.1088/1361-6528/ac7ac0 .

Vukadinović, Aleksandar, Milanović, Zorana, Ognjanović, Miloš, Janković, Drina, Radović, Magdalena, Mirković, Marija D., Karageorgou, Maria-Argyro, Bouziotis, Penelope, Erić, Slavica, Vranješ-Đurić, Sanja, Antić, Bratislav, Prijović, Željko, "90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours" in Nanotechnology, 33, no. 40 (2022):405102,
https://doi.org/10.1088/1361-6528/ac7ac0 . .

TY  - JOUR
AU  - Karageorgou, Maria-Argyro
AU  - Rapsomanikis, Aristotelis-Nikolaos
AU  - Mirković, Marija D.
AU  - Vranješ-Đurić, Sanja
AU  - Stiliaris, Efstathios
AU  - Bouziotis, Penelope
AU  - Stamopoulos, Dimosthenis
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10405
AB  - The combination of two imaging modalities in a single agent has received increasing attention during the last few years, since its synergistic action guarantees both accurate and timely diagnosis. For this reason, dual-modality contrast agents (DMCAs), such as radiolabeled iron oxide (namely Fe3O4) nanoparticles, constitute a powerful tool in diagnostic applications. In this respect, here we focus on the synthesis of a potential single photon emission computed tomography/magnetic resonance imaging (SPECT/MRI) DMCA, which consists of Fe3O4 nanoparticles, surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) and radiolabeled with 99mTc, [99mTc]Tc-DPD-Fe3O4. The in vitro stability results showed that this DMCA is highly stable after 24 h of incubation in phosphate buffer saline (~92.3% intact), while it is adequately stable after 24 h of incubation with human serum (~67.3% intact). Subsequently, [99mTc]Tc-DPD-Fe3O4 DMCA was evaluated in vivo in mice models through standard biodistribution studies, MR imaging and gamma-camera imaging. All techniques provided consistent results, clearly evidencing noticeable liver uptake. Our work documents that [99mTc]Tc-DPD-Fe3O4 has all the necessary characteristics to be a potential DMCA.
T2  - Nanomaterials
T1  - 99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models
VL  - 12
IS  - 15
SP  - 2728
DO  - 10.3390/nano12152728
ER  - 

@article{
author = "Karageorgou, Maria-Argyro and Rapsomanikis, Aristotelis-Nikolaos and Mirković, Marija D. and Vranješ-Đurić, Sanja and Stiliaris, Efstathios and Bouziotis, Penelope and Stamopoulos, Dimosthenis",
year = "2022",
abstract = "The combination of two imaging modalities in a single agent has received increasing attention during the last few years, since its synergistic action guarantees both accurate and timely diagnosis. For this reason, dual-modality contrast agents (DMCAs), such as radiolabeled iron oxide (namely Fe3O4) nanoparticles, constitute a powerful tool in diagnostic applications. In this respect, here we focus on the synthesis of a potential single photon emission computed tomography/magnetic resonance imaging (SPECT/MRI) DMCA, which consists of Fe3O4 nanoparticles, surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) and radiolabeled with 99mTc, [99mTc]Tc-DPD-Fe3O4. The in vitro stability results showed that this DMCA is highly stable after 24 h of incubation in phosphate buffer saline (~92.3% intact), while it is adequately stable after 24 h of incubation with human serum (~67.3% intact). Subsequently, [99mTc]Tc-DPD-Fe3O4 DMCA was evaluated in vivo in mice models through standard biodistribution studies, MR imaging and gamma-camera imaging. All techniques provided consistent results, clearly evidencing noticeable liver uptake. Our work documents that [99mTc]Tc-DPD-Fe3O4 has all the necessary characteristics to be a potential DMCA.",
journal = "Nanomaterials",
title = "99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models",
volume = "12",
number = "15",
pages = "2728",
doi = "10.3390/nano12152728"
}

Karageorgou, M., Rapsomanikis, A., Mirković, M. D., Vranješ-Đurić, S., Stiliaris, E., Bouziotis, P.,& Stamopoulos, D.. (2022). 99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models. in Nanomaterials, 12(15), 2728.
https://doi.org/10.3390/nano12152728

Karageorgou M, Rapsomanikis A, Mirković MD, Vranješ-Đurić S, Stiliaris E, Bouziotis P, Stamopoulos D. 99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models. in Nanomaterials. 2022;12(15):2728.
doi:10.3390/nano12152728 .

Karageorgou, Maria-Argyro, Rapsomanikis, Aristotelis-Nikolaos, Mirković, Marija D., Vranješ-Đurić, Sanja, Stiliaris, Efstathios, Bouziotis, Penelope, Stamopoulos, Dimosthenis, "99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models" in Nanomaterials, 12, no. 15 (2022):2728,
https://doi.org/10.3390/nano12152728 . .

TY  - JOUR
AU  - Karageorgou, Maria-Argyro
AU  - Bouziotis, Penelope
AU  - Vranješ-Đurić, Sanja
AU  - Stamopoulos, Dimosthenis
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9043
AB  - Dual-modality contrast agents (DMCA), such as radiolabeled magnetic nanoparticles, have attracted significant attention in diagnostic applications due to their potency for the timely and accurate diagnosis of diseases. The hemocompatibility of a candidate DMCA with human blood is essential for the investigation of its application in vivo. In this respect, here we focused on the evaluation of the hemocompatibility of a new DMCA, that is based on iron oxide nanoparticles (i.e. Fe3O4 magnetite), with human red blood cells (RBCs). The specific iron oxide nanoparticles are surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (-DPD) and radiolabeled with gallium-68 (68Ga), resulting in 68Ga-DPD-Fe3O4. RBCs of five healthy individuals are incubated at room temperature for 120 min without and with 68Ga-DPD-Fe3O4 at concentrations 0.1 and 1.0 mg/ml. Optical microscopy (OM) and atomic force microscopy (AFM) are employed to assess detailed information on the overall morphological and geometrical characteristics of the entire cell at the microscopic (10−6 m) level and on the membrane morphology at the nanoscopic (10−9 m) level. In addition, a standard hematology analyzer (HA) is used to obtain complete blood count information. At the microscopic level, the combined OM, AFM and HA data revealed that the overall shape/size characteristics of RBCs were preserved upon incubation with 68Ga-DPD-Fe3O4. However, at the nanoscopic level, the AFM results revealed two different kinds of local deconstructions of the RBCs membrane, termed holes and ulcer-like abnormalities, that were observed in both the DMCA-free and DMCA-incubated samples. Holes did not exhibit any statistically significant difference upon incubation with the 68Ga-DPD-Fe3O4 DMCA. On the contrary, ulcer-like abnormalities exhibited two statistically significant differences upon incubation with the 68Ga-DPD-Fe3O4 DMCA. First, increased percentage of RBCs having at least one ulcer-like abnormality; in DMCA-incubated samples 78.6 ± 11.6% for CDMCA = 0.1 mg/ml and 80.4 ± 11.1% for CDMCA = 1.0 mg/ml, while in DMCA-free samples 61.2 ± 8.4% prior to and 63.6 ± 13.5% after incubation. Second, increased number of ulcer-like abnormalities per RBC; in DMCA-incubated samples 4.26 ± 0.62 for CDMCA = 0.1 mg/ml and 3.99 ± 0.97 for CDMCA = 1.0 mg/ml, while in DMCA-free samples 2.84 ± 0.54 prior to and 2.98 ± 0.50 after incubation. The combined OM, AFM and HA results prove fair hemocompatibility of the 68Ga-DPD-Fe3O4 DMCA with human RBCs, thus documenting its potential use in imaging applications.
T2  - Materials Science and Engineering: C
T1  - Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid
VL  - 115
SP  - 111121
DO  - 10.1016/j.msec.2020.111121
ER  - 

@article{
author = "Karageorgou, Maria-Argyro and Bouziotis, Penelope and Vranješ-Đurić, Sanja and Stamopoulos, Dimosthenis",
year = "2020",
abstract = "Dual-modality contrast agents (DMCA), such as radiolabeled magnetic nanoparticles, have attracted significant attention in diagnostic applications due to their potency for the timely and accurate diagnosis of diseases. The hemocompatibility of a candidate DMCA with human blood is essential for the investigation of its application in vivo. In this respect, here we focused on the evaluation of the hemocompatibility of a new DMCA, that is based on iron oxide nanoparticles (i.e. Fe3O4 magnetite), with human red blood cells (RBCs). The specific iron oxide nanoparticles are surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (-DPD) and radiolabeled with gallium-68 (68Ga), resulting in 68Ga-DPD-Fe3O4. RBCs of five healthy individuals are incubated at room temperature for 120 min without and with 68Ga-DPD-Fe3O4 at concentrations 0.1 and 1.0 mg/ml. Optical microscopy (OM) and atomic force microscopy (AFM) are employed to assess detailed information on the overall morphological and geometrical characteristics of the entire cell at the microscopic (10−6 m) level and on the membrane morphology at the nanoscopic (10−9 m) level. In addition, a standard hematology analyzer (HA) is used to obtain complete blood count information. At the microscopic level, the combined OM, AFM and HA data revealed that the overall shape/size characteristics of RBCs were preserved upon incubation with 68Ga-DPD-Fe3O4. However, at the nanoscopic level, the AFM results revealed two different kinds of local deconstructions of the RBCs membrane, termed holes and ulcer-like abnormalities, that were observed in both the DMCA-free and DMCA-incubated samples. Holes did not exhibit any statistically significant difference upon incubation with the 68Ga-DPD-Fe3O4 DMCA. On the contrary, ulcer-like abnormalities exhibited two statistically significant differences upon incubation with the 68Ga-DPD-Fe3O4 DMCA. First, increased percentage of RBCs having at least one ulcer-like abnormality; in DMCA-incubated samples 78.6 ± 11.6% for CDMCA = 0.1 mg/ml and 80.4 ± 11.1% for CDMCA = 1.0 mg/ml, while in DMCA-free samples 61.2 ± 8.4% prior to and 63.6 ± 13.5% after incubation. Second, increased number of ulcer-like abnormalities per RBC; in DMCA-incubated samples 4.26 ± 0.62 for CDMCA = 0.1 mg/ml and 3.99 ± 0.97 for CDMCA = 1.0 mg/ml, while in DMCA-free samples 2.84 ± 0.54 prior to and 2.98 ± 0.50 after incubation. The combined OM, AFM and HA results prove fair hemocompatibility of the 68Ga-DPD-Fe3O4 DMCA with human RBCs, thus documenting its potential use in imaging applications.",
journal = "Materials Science and Engineering: C",
title = "Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid",
volume = "115",
pages = "111121",
doi = "10.1016/j.msec.2020.111121"
}

Karageorgou, M., Bouziotis, P., Vranješ-Đurić, S.,& Stamopoulos, D.. (2020). Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid. in Materials Science and Engineering: C, 115, 111121.
https://doi.org/10.1016/j.msec.2020.111121

Karageorgou M, Bouziotis P, Vranješ-Đurić S, Stamopoulos D. Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid. in Materials Science and Engineering: C. 2020;115:111121.
doi:10.1016/j.msec.2020.111121 .

Karageorgou, Maria-Argyro, Bouziotis, Penelope, Vranješ-Đurić, Sanja, Stamopoulos, Dimosthenis, "Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid" in Materials Science and Engineering: C, 115 (2020):111121,
https://doi.org/10.1016/j.msec.2020.111121 . .

TY  - JOUR
AU  - Spirou, Spiridon
AU  - Costa Lima, Sofia
AU  - Bouziotis, Penelope
AU  - Vranješ-Đurić, Sanja
AU  - Efthimiadou, Eleni
AU  - Laurenzana, Anna
AU  - Barbosa, Ana
AU  - Garcia-Alonso, Ignacio
AU  - Jones, Carlton
AU  - Janković, Drina
AU  - Gobbo, Oliviero
PY  - 2018
UR  - http://www.mdpi.com/2079-4991/8/5/306
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7707
AB  - Magnetic nanoparticle (MNP)-mediated hyperthermia (MH) coupled with radiation therapy (RT) is a novel approach that has the potential to overcome various practical difficulties encountered in cancer treatment. In this work, we present recommendations for the in vitro and in vivo testing and application of the two treatment techniques. These recommendations were developed by the members of Working Group 3 of COST Action TD 1402: Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (“Radiomag”). The purpose of the recommendations is not to provide definitive answers and directions but, rather, to outline those tests and considerations that a researcher must address in order to perform in vitro and in vivo studies. The recommendations are divided into 5 parts: (a) in vitro evaluation of MNPs; (b) in vitro evaluation of MNP-cell interactions; (c) in vivo evaluation of the MNPs; (d) MH combined with RT; and (e) pharmacokinetic studies of MNPs. Synthesis and characterization of the MNPs, as well as RT protocols, are beyond the scope of this work.
T2  - Nanomaterials
T1  - Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy
VL  - 8
IS  - 5
SP  - 306
DO  - 10.3390/nano8050306
ER  - 

@article{
author = "Spirou, Spiridon and Costa Lima, Sofia and Bouziotis, Penelope and Vranješ-Đurić, Sanja and Efthimiadou, Eleni and Laurenzana, Anna and Barbosa, Ana and Garcia-Alonso, Ignacio and Jones, Carlton and Janković, Drina and Gobbo, Oliviero",
year = "2018",
abstract = "Magnetic nanoparticle (MNP)-mediated hyperthermia (MH) coupled with radiation therapy (RT) is a novel approach that has the potential to overcome various practical difficulties encountered in cancer treatment. In this work, we present recommendations for the in vitro and in vivo testing and application of the two treatment techniques. These recommendations were developed by the members of Working Group 3 of COST Action TD 1402: Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (“Radiomag”). The purpose of the recommendations is not to provide definitive answers and directions but, rather, to outline those tests and considerations that a researcher must address in order to perform in vitro and in vivo studies. The recommendations are divided into 5 parts: (a) in vitro evaluation of MNPs; (b) in vitro evaluation of MNP-cell interactions; (c) in vivo evaluation of the MNPs; (d) MH combined with RT; and (e) pharmacokinetic studies of MNPs. Synthesis and characterization of the MNPs, as well as RT protocols, are beyond the scope of this work.",
journal = "Nanomaterials",
title = "Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy",
volume = "8",
number = "5",
pages = "306",
doi = "10.3390/nano8050306"
}

Spirou, S., Costa Lima, S., Bouziotis, P., Vranješ-Đurić, S., Efthimiadou, E., Laurenzana, A., Barbosa, A., Garcia-Alonso, I., Jones, C., Janković, D.,& Gobbo, O.. (2018). Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. in Nanomaterials, 8(5), 306.
https://doi.org/10.3390/nano8050306

Spirou S, Costa Lima S, Bouziotis P, Vranješ-Đurić S, Efthimiadou E, Laurenzana A, Barbosa A, Garcia-Alonso I, Jones C, Janković D, Gobbo O. Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. in Nanomaterials. 2018;8(5):306.
doi:10.3390/nano8050306 .

Spirou, Spiridon, Costa Lima, Sofia, Bouziotis, Penelope, Vranješ-Đurić, Sanja, Efthimiadou, Eleni, Laurenzana, Anna, Barbosa, Ana, Garcia-Alonso, Ignacio, Jones, Carlton, Janković, Drina, Gobbo, Oliviero, "Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy" in Nanomaterials, 8, no. 5 (2018):306,
https://doi.org/10.3390/nano8050306 . .

TY  - JOUR
AU  - Karageorgou, Maria-Argyro
AU  - Vranješ-Đurić, Sanja
AU  - Radović, Magdalena
AU  - Lyberopoulou, Anna
AU  - Antić, Bratislav
AU  - Rouchota, Maritina
AU  - Gazouli, Maria
AU  - Loudos, George
AU  - Xanthopoulos, Stavros
AU  - Sideratou, Zili
AU  - Stamopoulos, Dimosthenis
AU  - Bouziotis, Penelope
AU  - Tsoukalas, Charalampos
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1903
AB  - The aim of this study was to develop a dual-modality PET/MR imaging probe by radiolabeling iron oxide magnetic nanoparticles (IONPs), surface functionalized with water soluble stabilizer 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD), with the positron emitter Gallium-68. Magnetite nanoparticles (Fe3O4 MNPs) were synthesized via coprecipitation method and were stabilized with DPD. The Fe3O4-DPD MNPs were characterized based on their structure, morphology, size, surface charge, and magnetic properties. In vitro cytotoxicity studies showed reduced toxicity in normal cells, compared to cancer cells. Fe3O4-DPD MNPs were successfully labeled with Gallium-68 at high radiochemical purity ( GT 91%) and their stability in human serum and in PBS was demonstrated, along with their further characterization on size and magnetic properties. The ex vivo biodistribution studies in normal Swiss mice showed high uptake in the liver followed by spleen. The acquired PET images were in accordance with the ex vivo biodistribution results. Our findings indicate that 68 Ga-Fe3O4-DPD MNPs could serve as an important diagnostic tool for biomedical imaging.
T2  - Contrast Media and Molecular Imaging
T1  - Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study
DO  - 10.1155/2017/6951240
ER  - 

@article{
author = "Karageorgou, Maria-Argyro and Vranješ-Đurić, Sanja and Radović, Magdalena and Lyberopoulou, Anna and Antić, Bratislav and Rouchota, Maritina and Gazouli, Maria and Loudos, George and Xanthopoulos, Stavros and Sideratou, Zili and Stamopoulos, Dimosthenis and Bouziotis, Penelope and Tsoukalas, Charalampos",
year = "2017",
abstract = "The aim of this study was to develop a dual-modality PET/MR imaging probe by radiolabeling iron oxide magnetic nanoparticles (IONPs), surface functionalized with water soluble stabilizer 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD), with the positron emitter Gallium-68. Magnetite nanoparticles (Fe3O4 MNPs) were synthesized via coprecipitation method and were stabilized with DPD. The Fe3O4-DPD MNPs were characterized based on their structure, morphology, size, surface charge, and magnetic properties. In vitro cytotoxicity studies showed reduced toxicity in normal cells, compared to cancer cells. Fe3O4-DPD MNPs were successfully labeled with Gallium-68 at high radiochemical purity ( GT 91%) and their stability in human serum and in PBS was demonstrated, along with their further characterization on size and magnetic properties. The ex vivo biodistribution studies in normal Swiss mice showed high uptake in the liver followed by spleen. The acquired PET images were in accordance with the ex vivo biodistribution results. Our findings indicate that 68 Ga-Fe3O4-DPD MNPs could serve as an important diagnostic tool for biomedical imaging.",
journal = "Contrast Media and Molecular Imaging",
title = "Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study",
doi = "10.1155/2017/6951240"
}

Karageorgou, M., Vranješ-Đurić, S., Radović, M., Lyberopoulou, A., Antić, B., Rouchota, M., Gazouli, M., Loudos, G., Xanthopoulos, S., Sideratou, Z., Stamopoulos, D., Bouziotis, P.,& Tsoukalas, C.. (2017). Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study. in Contrast Media and Molecular Imaging.
https://doi.org/10.1155/2017/6951240

Karageorgou M, Vranješ-Đurić S, Radović M, Lyberopoulou A, Antić B, Rouchota M, Gazouli M, Loudos G, Xanthopoulos S, Sideratou Z, Stamopoulos D, Bouziotis P, Tsoukalas C. Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study. in Contrast Media and Molecular Imaging. 2017;.
doi:10.1155/2017/6951240 .

Karageorgou, Maria-Argyro, Vranješ-Đurić, Sanja, Radović, Magdalena, Lyberopoulou, Anna, Antić, Bratislav, Rouchota, Maritina, Gazouli, Maria, Loudos, George, Xanthopoulos, Stavros, Sideratou, Zili, Stamopoulos, Dimosthenis, Bouziotis, Penelope, Tsoukalas, Charalampos, "Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study" in Contrast Media and Molecular Imaging (2017),
https://doi.org/10.1155/2017/6951240 . .

TY  - CONF
AU  - Koumarianou, Eftichia
AU  - Bouziotis, Penelope
AU  - Kumrić, Ksenija
AU  - Fragogeorgi, I
AU  - Loudos, GK
AU  - Mitsokapas, N
AU  - Varvarigou, AD
AU  - Archimandritis, Spyridon
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6463
C3  - European Journal of Nuclear Medicine and Molecular Imaging
T1  - Production of Lu-177 at the NCSR Demokritos. Labeling of biomolecules with Lutetium-177 and purification of the labeled product
VL  - 31
SP  - S389
EP  - S389
UR  - https://hdl.handle.net/21.15107/rcub_vinar_6463
ER  - 

@conference{
author = "Koumarianou, Eftichia and Bouziotis, Penelope and Kumrić, Ksenija and Fragogeorgi, I and Loudos, GK and Mitsokapas, N and Varvarigou, AD and Archimandritis, Spyridon",
year = "2004",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
title = "Production of Lu-177 at the NCSR Demokritos. Labeling of biomolecules with Lutetium-177 and purification of the labeled product",
volume = "31",
pages = "S389-S389",
url = "https://hdl.handle.net/21.15107/rcub_vinar_6463"
}

Koumarianou, E., Bouziotis, P., Kumrić, K., Fragogeorgi, I., Loudos, G., Mitsokapas, N., Varvarigou, A.,& Archimandritis, S.. (2004). Production of Lu-177 at the NCSR Demokritos. Labeling of biomolecules with Lutetium-177 and purification of the labeled product. in European Journal of Nuclear Medicine and Molecular Imaging, 31, S389-S389.
https://hdl.handle.net/21.15107/rcub_vinar_6463

Koumarianou E, Bouziotis P, Kumrić K, Fragogeorgi I, Loudos G, Mitsokapas N, Varvarigou A, Archimandritis S. Production of Lu-177 at the NCSR Demokritos. Labeling of biomolecules with Lutetium-177 and purification of the labeled product. in European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:S389-S389.
https://hdl.handle.net/21.15107/rcub_vinar_6463 .

Koumarianou, Eftichia, Bouziotis, Penelope, Kumrić, Ksenija, Fragogeorgi, I, Loudos, GK, Mitsokapas, N, Varvarigou, AD, Archimandritis, Spyridon, "Production of Lu-177 at the NCSR Demokritos. Labeling of biomolecules with Lutetium-177 and purification of the labeled product" in European Journal of Nuclear Medicine and Molecular Imaging, 31 (2004):S389-S389,
https://hdl.handle.net/21.15107/rcub_vinar_6463 .

TY  - JOUR
AU  - Fani, M
AU  - Vranješ, Sanja
AU  - Archimandritis, Spyridon
AU  - Potamianos, S
AU  - Xanthopoulos, S
AU  - Bouziotis, Penelope
AU  - Varvarigou, AD
PY  - 2002
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2557
AB  - The labeling of a monoclonal (anti-CEA) and a polyclonal (IgG) antibody with Sm-153 has been investigated, using the bicyclic anhydride of DTPA (cDTPAa) as the chelating agent. The radiochemical study was performed using a combination of radioanalytical techniques (gel filtration, HPLC, ITLC-SG and SDS-PAGE). Optimization of factors affecting labeling (pH, Ab, Ab-DTPA concentration, etc.) leads to a labeling yield higher than 90%. Biodistribution studies in normal mice showed slow blood clearance and high uptake into the liver, kidney and lungs. (C) 2002 Elsevier Science Ltd. All rights reserved.
T2  - Applied Radiation and Isotopes
T1  - Labeling of monoclonal antibodies with Sm-153 for potential use in radioimmunotherapy
VL  - 57
IS  - 5
SP  - 665
EP  - 674
DO  - 10.1016/S0969-8043(02)00181-1
ER  - 

@article{
author = "Fani, M and Vranješ, Sanja and Archimandritis, Spyridon and Potamianos, S and Xanthopoulos, S and Bouziotis, Penelope and Varvarigou, AD",
year = "2002",
abstract = "The labeling of a monoclonal (anti-CEA) and a polyclonal (IgG) antibody with Sm-153 has been investigated, using the bicyclic anhydride of DTPA (cDTPAa) as the chelating agent. The radiochemical study was performed using a combination of radioanalytical techniques (gel filtration, HPLC, ITLC-SG and SDS-PAGE). Optimization of factors affecting labeling (pH, Ab, Ab-DTPA concentration, etc.) leads to a labeling yield higher than 90%. Biodistribution studies in normal mice showed slow blood clearance and high uptake into the liver, kidney and lungs. (C) 2002 Elsevier Science Ltd. All rights reserved.",
journal = "Applied Radiation and Isotopes",
title = "Labeling of monoclonal antibodies with Sm-153 for potential use in radioimmunotherapy",
volume = "57",
number = "5",
pages = "665-674",
doi = "10.1016/S0969-8043(02)00181-1"
}

Fani, M., Vranješ, S., Archimandritis, S., Potamianos, S., Xanthopoulos, S., Bouziotis, P.,& Varvarigou, A.. (2002). Labeling of monoclonal antibodies with Sm-153 for potential use in radioimmunotherapy. in Applied Radiation and Isotopes, 57(5), 665-674.
https://doi.org/10.1016/S0969-8043(02)00181-1

Fani M, Vranješ S, Archimandritis S, Potamianos S, Xanthopoulos S, Bouziotis P, Varvarigou A. Labeling of monoclonal antibodies with Sm-153 for potential use in radioimmunotherapy. in Applied Radiation and Isotopes. 2002;57(5):665-674.
doi:10.1016/S0969-8043(02)00181-1 .

Fani, M, Vranješ, Sanja, Archimandritis, Spyridon, Potamianos, S, Xanthopoulos, S, Bouziotis, Penelope, Varvarigou, AD, "Labeling of monoclonal antibodies with Sm-153 for potential use in radioimmunotherapy" in Applied Radiation and Isotopes, 57, no. 5 (2002):665-674,
https://doi.org/10.1016/S0969-8043(02)00181-1 . .